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Introduction: Current pathophysiological hypotheses of Gilles de la Tourette Syndrome
(GTS) refer to temporally abnormal neuronal activation in cortico-striato-thalamo-cortical
(CSTC) networks. Modifying cortical activity by non-invasive brain-stimulation appears to
be a new treatment option in GTS.
Background: Previous studies suggested therapeutic effects of cathodal transcranial
direct current stimulation (tDCS) to pre-supplementary motor areas (SMA),
however, treatment modalities concerning electrode placement, current intensity and
stimulation-rate have not been systematically explored. Aim of this study was to assess
efficacy of an alternative stimulation regime on GTS symptoms in a pilot study. To test a
treatment protocol with tDCS twice a day, we administered 10 sessions over 5 days of
bilateral cathodal tDCS (30 min, 2 mA) over the pre-SMA in three patients with severe
GTS. Tic severity as well as obsessive-compulsive (OC) symptoms and affective scales
were rated before and after tDCS treatment.
Discussion: Only one out of three patients showed a 34.5% reduction in tic severity.
The two other patients showed an increase in tic severity. All patients showed a mild
increase in positive affect and a reduction in negative affect, OC symptom changes
were heterogeneous. Our results do not support earlier findings of extensive therapeutic
effects of cathodal tDCS on tics in patients with GTS and show that prediction of
stimulation effects on a targeted brain area remains inaccurate.
Concluding Remarks: Future research will have to focus on the determination of most
effective stimulation modes regarding site, polarity and frequency of tDCS in GTS
patients.
Keywords: tDCS, transcranial direct current stimulation, GTS, tourette syndrome, supplementary motor areas,
OCD, obsessive compulsive disorder
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INTRODUCTION
Gilles de la Tourette syndrome (GTS) is a neuropsychiatric
disorder with chronic motor and vocal tics, manifesting in the
course of childhood and early adolescence. Tics are usually
preceded by premonitory urges and can be suppressed at
will. The disorder is self-limiting in at least 44% of all
cases and symptoms tend to significantly decrease in early
adulthood. Still there are 22% of adult patients retaining clinically
significant symptoms despite adequate medication (Leckman
et al., 1998; Burd et al., 2001; Pappert et al., 2003; Evans
et al., 2016). Approved pharmacological treatment consists of
alpha-2-adreno-receptor-blockers, and distinct antipsychotics.
Both groups of medications are associated with mild to severe
side effects including sedation, cardiovascular dysregulation,
extrapyramidal motor symptoms (EPMS), sexual dysfunction,
weight gain or cardiac risks that are scarcely tolerated by patients.
Moreover, depression and anxiety are common co-morbid
disorders in adult GTS patients (Evans et al., 2016), and there
is an additional need for specific treatment in these domains.
Psychotherapeutic treatment such as habit reversal training or
exposure with response prevention require sufficient adherence
while also yielding only incomplete remission rates (Capriotti
et al., 2014). Tic manifestation in GTS is usually referred
to an organic etiology. Functional neuroimaging has revealed
that tic symptoms originate from a dysregulation of cortico-
striato-thalamo-cortical (CSTC) networks. Results show a down
regulation of movement inhibition in caudate and anterior
cingulate cortex and an hyperactivation of motor pathways in
putamen, pallidum and substania nigra, as well as in cortical
regions of the sensorimotor cortex with cortical hyperactivation
in pre-motor regions preceding basal ganglia activation (Wang
et al., 2011). Therefore, modulation of basal ganglia function
by deep brain stimulation (DBS) might offer a third track of
treatment besides psychopharmacology and psychotherapy. DBS
has shown promising results in GTS while resulting in high
operative risk and diverse side effects, restricting treatment to
a severely affected group of adult patients (Visser-Vandewalle
et al., 2014; Schrock et al., 2015). In summary, treatment
alternatives are sparse and results are dissatisfying due to lack
in treatment response or extensive side effects. In view of the
success in DBS and the implication of cortical dysregulation,
non-invasive brain stimulation (NIBS) appears a viable choice
without the risk of invasive treatments. Repetitive transcranial
magnetic stimulation (rTMS), inducing an electric current in
cortical regions via a pulsed magnetic field, has been shown
to be efficient in tic reduction when applied at 1 Hz over the
supplementary motor area (SMA; Mantovani et al., 2006). In
children, positive results lasted at least 6 months (Le et al., 2013).
However these studies were open label without sham control.
Landeros-Weisenberger et al. (2015) presented the first sham
controlled double-blind rTMS study in patients with severe GTS
and could not show a significant difference in tic improvement
after active rTMS compared to sham rTMS. Thus, results of
rTMS in the treatment of GTS are controversial so far (Kious
et al., 2016; Pedroarena-Leal and Ruge, 2017). Another emerging
NIBS technique, transcranial direct current stimulation (tDCS)
has been shown to modulate motor cortex excitability (Nitsche
and Paulus, 2001) and frontal network activity (Keeser et al.,
2011a). The modulation of large scale brain networks close
to the stimulation site and in remote areas could serve as a
surrogate for a hypothesized influence of tDCS on activation
in basal ganglia. Altering activity in whole-brain networks by
stimulation of specific nodes has been proposed as a mode of
treatment in GTS, while the appropriate dosage and targets
remain to be established (Pedroarena-Leal and Ruge, 2017). tDCS
is considered safe, with very limited side effects, such as itching
of the skin, light headaches or dizziness (Nitsche et al., 2003;
Bikson et al., 2016). Commonly, daily treatment is performed
in acute phases of disease and intermittent and even home
treatment are being explored in chronic therapeutic settings
(Charvet et al., 2015; Palm et al., 2018) and in phases of remission,
treatment-free periods can be elongated according to individual
patient needs. These options appear especially appealing in a
usually young and mentally unimpaired patient group such as
GTS patients.
In tDCS, polarity of stimulation over the affected cortical
region is a determinant of treatment effects. Cathodal stimulation
is thought to have inhibiting effects, while anodal stimulation
inversely has increasing effects on cortical excitability (Nitsche
and Paulus, 2001). As functional magnetic resonance imaging
(fMRI) revealed increased activity preceding tic manifestation
in cortical pre-motor and motor regions (Wang et al., 2011),
cathodal tDCS over these areas may reduce excitability in these
regions. Previous findings in single GTS patients suggested
therapeutic effects of cathodal tDCS of pre-SMA both via
monolateral treatment of the most affected side or bilateral
treatment, with extracephalic anodal reference electrodes,
respectively (Mrakic-Sposta et al., 2008; Carvalho et al., 2015).
Though randomized controlled clinical trials (RCT) investigating
tDCS in GTS are lacking, further data together with an RCT
protocol have been published recently (Eapen et al., 2017).
There, patients will be treated with 18 sessions of 1.4 mA
tDCS with the cathode positioned over SMA area and the
reference electrode over the right deltoid muscle. At least one
of the two pilot patients showed relevant improvement of tic
severity during treatment period. As optimal tDCS parameters
have not been identified to date, we investigated twice-daily
sessions of bilateral cathodal tDCS over the pre-SMA for
5 days in three patients with GTS. This approach aims to
assess a different stimulation regime from previous studies to
further knowledge on stimulation effects in patients with this
condition.
MATERIALS AND METHODS
Three GTS patients from the Department of Psychiatry,
University of Munich, underwent twice-daily tDCS treatment
for 5 days. All patients gave their written informed consent
for an individual treatment attempt by use of tDCS as an
experimental compassionate use and agreed on their data being
anonymously published after completion of the treatment.
Pre-existing pharmacological treatment was not altered before or
during tDCS treatment and, if receiving psychopharmacologic
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drugs, patients had a stable dosage for at least 3 weeks without
change of motor symptoms.
Transcranial Direct Current Stimulation
Two milliampere tDCS was applied twice a day for 30 min
(in total 10 stimulations in 5 days) following previous findings
on safety of repeated twice-daily tDCS in depressive disorders
(Palm et al., 2015). Both tDCS sessions were performed in
the morning to avoid further circadian influences and were
separated by an interval of approximately 3 h (e.g., 8:00, 11:00).
Two independent stimulators were used parallel to stimulate
both hemispheres. Cathodal stimulation was performed using
rectangular 7 × 5 cm = 35 cm2 saline soaked sponge electrodes,
placed bilaterally and longitudinally over motor areas of the
cortex (C3, C4, according to 10-20 EEG system) with 1 cm space
between them (Figure 1). With this montage, SMA and pre-SMA
areas were also covered. Anodal electrodes were each fixed with
adhesive tape ipsilateral over the sternocleidomastoid muscle
(extracephalic electrodes). Direct current was applied with an
eldithr DC-stimulator (neuroConn, Ilmenau, Germany). For
better tolerance, stimulation was ramped up and ramped down
over 15 s.
Measurements
Before and after tDCS series, the following questionnaires
were administered: Yale Global Tic Severity Scale (YGTSS;
Leckman et al., 1989; Storch et al., 2005) to quantify tic severity,
Yale-Brown Obsessive Compulsive Scale (Y-BOCS; Goodman
et al., 1989) to assess obsessive and compulsive behavior and the
Positive and Negative Affect Schedule (PANAS; Krohne et al.,
1996) to evaluate affective symptoms. Tic frequency was assessed
by counting tics during a 3 min interval while sitting at rest in a
quiet room. To evaluate the effect of tDCS, percentage changes of
data obtained at day five as compared to results at baseline were
calculated.
PATIENT CHARACTERISTICS AND
CLINICAL HISTORY
The first patient (P1), a 55 year old male, presented with
simple motor and simple vocal tics (age at onset: 9/10 years)
as well as obsessive compulsive disorder (OCD). Motor tics
included grimacing, grinding of teeth, tensing of shoulder
and nuchal muscles, increasing during times of rest and
stressful situations. Vocal tics included loud exclamations,
sniffing, harrumphing or grunting. Tic frequency was
low. OCD symptoms included compulsive checking and
writing. Current medication was limited to antihypertensive
medication (candesartan 8 mg/day), previous treatment with
aripiprazole showed slight reduction in tic frequency with
unacceptable side effects of extensive weight gain and was
discontinued 4 years ago. Psychotherapeutic treatment was
FIGURE 1 | Dorsal lateral view (A) and lateral view (B; Soterix Medical HD-ExploreTM). Cathodal electrodes (7 × 5 cm = 35 cm2) were placed bilaterally over
(pre-)motor cortical areas (C3, C4) with 1 cm space in between. Anodal electrodes were placed ipsilateral over the sternocleidomastoid muscle. Current strength of
2 mA was applied for 30 min.
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limited to treatment for OCD symptoms several months before
undergoing tDCS.
The second patient (P2), a 20 year old male, presented
with simple motor and simple vocal tics (age at onset:
16 years). P2 did not show any OCD symptoms. Motor tics
included striking out of both arms (with ensuing self-harming
effects), jerking of the head and facial muscles. Vocal
tics included barking and uttering of syllables. Current
treatment consisted of atypical antipsychotics (tiapride
600 mg/day, olanzapine 15 mg/day). Previous treatment
also comprised atypical antipsychotics (risperidone, amisulpride,
aripiprazole, olanzapine and quetiapine). The patient
showed a history of substance-induced psychotic symptoms
(tetrahydrocannabinol and ‘‘spice’’) without current use of
illegal substances and was abstinent since 3 years. He also
exhibited dissociative seizures during youth that have been
treated successfully by an alternative practitioner by eye
movement desensitization and reprocessing (EMDR) and
hypnosis.
The third patient (P3), an 18 year old female, presented with
frequent simple and complex motor as well as vocal tics (age at
onset: 14 years). She was also suffering from OCD symptoms.
Motor tics included hitting own thorax and pelvis with her
fists, flipping, grimacing, jerking of the head, shoulders and
hands, gesturing (Russian roulette), saluting and locking her
feet while walking. Vocal tics included harrumphing, whistling,
caterwauling, uttering syllables, words, limited sentences and
echolalia. Tic-free sequences were short (max. 1 min), urges
to perform tics were rated very high by the patient. OCD
symptoms included compulsive counting, repeating, checking
and arranging/collocating. Current treatment consisted of
risperidone 6 mg/day and biperiden 4 mg/day in a stable
dose for 3 weeks. Previous treatment included antidepressants
and atypical antipsychotics (fluoxetine 30 mg/day, aripiprazole
10 mg/day, tiapride 600 mg/day, and quetiapine in unknown
dosage) and was discontinued more than 1 year before due to
symptom-alleviation (fluoxetine) or lack in positive therapeutic
outcome or inacceptable side effects (aripiprazole, tiapride,
quetiapine).
RESULTS
All patients completed twice daily sessions of tDCS for 5 days
and stimulations were generally well tolerated. Side effects were
mild skin irritation in P1 due to adhesive tape over the electrode,
mild headache and metallic taste during stimulation in P2,
none in P3.
FIGURE 2 | Yale Global Tic Severity Scale (YGTSS) scores of patients 1–3.
x-axis shows measuring time points, y-axis shows YGTSS score.
Prior to stimulation, global tic severity scores (YGTSS), not
including general impairment scores, were rated at 29, 38 and
36 points for patients 1, 2 and 3, respectively. After tDCS
for 5 days, tic-severity decreased in patient 1 by 10 points to
finally 19 points. Both patients 2 and 3 showed an increase in
tic-severity by 5 points to 43 points (P2) and 2 points to 38 points
(P3, Figure 2). General impairment scores as measured by the
YGTSS did not differ in comparison between pre and post tDCS
measurements. P1 showed impairment of 10 points, P2 30 points
and P3 50 points.
OCD symptoms were present only in patients 1 and 3,
rated at 18 and 10 points, respectively. Patient 1 reported a
reduction of 83.3% in OCD symptoms following stimulation.
Patient 3 showed an increase of 20% in OCD symptoms.
Affective symptoms were self-rated and categorized into
PANAS negative and positive subscores. All three patients
expressed a decrease in negative and an increase in positive mood
following stimulation. Most notable changes occurred in patient
2 with an increase of positive affect of 30.8% and a decrease of
negative affect of 20%.
The 3 min tic-count showed high inter-individual variability,
patients 1 and 2 experienced 11 and 19 tics in 3 min, whereas
patient 3 experienced 218 tics in 3 min. Surprisingly, contrary
to the reduction in tic severity observed in patient 1, tic-counts
showed an increase in all three subjects, following stimulation
(increases by 18.2% in patient 1, by 200% in patient 2 and by
70.2% in patient 3). Clinical data is reported in Table 1.
TABLE 1 | Clinical rating before (pre) and after (post) transcranial direct current stimulation (tDCS) treatment for 5 days.
Tests Patient 1 Patient 2 Patient 3
pre post ∆ [%] pre post ∆ [%] pre post ∆ [%]
YGTSS 29 19 −34.5 38 43 13.2 36 38 5.6
YBOCS 18 3 −83.3 0 0 0.0 10 12 20.0
PANAS neg. 17 16 −5.9 15 12 −20.0 23 19 −17.4
PANAS pos. 34 35 2.9 26 34 30.8 26 27 3.8
tic count (3 min) 11 13 18.2 19 57 200.0 218 371 70.2
Frontiers in Behavioral Neuroscience | www.frontiersin.org 4 August 2018 | Volume 12 | Article 194
Behler et al. tDCS for GTS
DISCUSSION
Here, we report three cases of GTS patients undergoing bilateral
cathodal tDCS of SMA and pre-SMA areas. This intervention
did not decrease tic severity in two out of three patients. Only
one patient reported a reduction of tic severity, but even more
marked of OCD symptoms. In contrast, an increase in tic severity
was observed in the other two subjects. All subjects showed an
increase in 3 min tic count and a decrease in negative emotions
following stimulation as well as a slight increase in positive affect.
Thus, the current tDCS protocol over SMA and pre-SMA areas
was not successful in treating GTS core symptoms in contrast to
previous studies (Mrakic-Sposta et al., 2008; Carvalho et al., 2015;
Eapen et al., 2017).
There are clear limitations of our approach: first, the problem
of natural waxing and waning of tics in GTS which is adding
to the issue of the very small sample size of our observation.
Second, the heterogeneous clinical characteristics of our patients
and the variance of co-medication (Brunoni et al., 2012; Nitsche
et al., 2012) may impact on stimulation efficacy, but also reflect a
disorder with frequent and typical side diagnoses and insufficient
efficacy of singular pharmacotherapy. Of note, regarding GTS
epidemiology, P2 and P3 showed an untypically late onset of
tics at the age of 16 and 14 years respectively and did not
show any therapeutic efficacy, whereas P1 had a more typical
tic onset at 9 years of age and showed a decrease in tic severity
following tDCS. This difference in age at onset might constitute
an indicator for efficacy of tDCS in GTS, eventually referring to
differences in pathology and etiology. A major limitation is the
lack of a sham tDCS condition, however, the application of tDCS
was for compassionate use and not part of a study protocol. Thus,
all effects observed may be due to placebo or nocebo effects of
stimulation.
Concerning stimulation parameters, i.e., current strength,
duration and number of sessions per day, we deviated from
previously reported cases in GTS and this also might have
contributed to our negative result. In this respect our case series
was rather designed to empirically explore a new stimulation
regime than to reproduce and validate earlier findings, since
to this end, larger controlled trials would be needed rather
than small case series. In comparison, Carvalho et al. (2015)
applied a more focal stimulation, using smaller surface electrodes
that presumably resulted in a more specific stimulation of the
pre-SMA. Similarly, Mrakic-Sposta et al. (2008) used smaller
electrodes but applied current more generally over the motor
cortex, and Eapen et al. (2017) applied electrodes with a size
of 25 cm2 over the anterior portion of the SMA. Although
supported by evidence of the proposed parameters in the
treatment of major depression (Palm et al., 2016) and taking
into account a lack in large controlled studies on effective
stimulation parameters in GTS, our less focal approach may
not have been an optimal mode of stimulation. However
positioning of reference electrodes is the same across cases
with extracephalic placement over right deltoid muscle (Mrakic-
Sposta et al., 2008; Carvalho et al., 2015; Eapen et al., 2017)
whereas we used an ipsilateral montage on sternocleidomastoid
muscles.
A further difference was the use of 2 mA intensity here
and in Mrakic-Sposta et al.’s (2008) study instead of 1.4 mA
(Carvalho et al., 2015; Eapen et al., 2017). This intensity has
been selected based on our experimental studies of prefrontal
tDCS in humans (Keeser et al., 2011a,b) and treatment parameter
for major depression (Brunoni et al., 2013). These empirically
established parameters were adopted from recent findings in
the treatment of major depression where a tDCS relationship
between total dosage and efficacy of stimulation was found
(Brunoni et al., 2016), but these results are restricted to
anodal prefrontal stimulation. Therefore, our cathodal tDCS
protocol was rather comparable to the protocol applied in a
randomized controlled trial in OCD by D’Urso et al. (2016).
Interestingly, the largest and clinically meaningful effect was
not found on GTS, but on OCD symptoms, i.e., a reduction in
YBOCS score in P1. However, nonlinear dose dependency has
been proposed as a principle of action in tDCS. Research on
motor cortex stimulation has shown that previously postulated
inhibiting effects of cathodal stimulation as well as exciting
effects of anodal stimulation might be inversed depending
on ground activity of stimulated tissue, current intensity and
frequentness of stimulation (Brunoni et al., 2012; Batsikadze
et al., 2013). It is likely that the impact of the stimulation
parameters, i.e., current strength, polarity, duration and interval
between stimulations, strictly depends on the stimulated area
and might have led to counter regulatory or homeostatic
plasticity effects in motor cortical areas as previously shown
in neurophysiology studies (Nitsche and Paulus, 2001; Monte-
Silva et al., 2010). Therefore, the mere transmission of those
anodal stimulation parameters used to enhance dorsolateral
prefrontal function in depressed patients to a hypothesized
decrease of hyperactivity by cathodal motor cortex stimulation
in GTS patients might induce unwanted non-linear, even
inverse effects. Here, guidance on stimulation intensity, duration,
and frequentness is still lacking and therapeutic options are
restricted to empirical considerations. The issue of a critical
dosage has been very recently emphasized in a rat model of
GTS where different polarities and current intensities were
applied (Edemann-Callesen et al., 2018). There, tDCS showed
a polarity-specific (anodal) and non-linear intensity dependent
(i.e., 200 µA as the only effective tDCS intensity) reduction
of repetitive behavior in DAT-tg rats with hyperresponsive
dopaminergic system in comparison to wildtype rats. The
authors hypothesize that tDCS restores previously imbalanced
sensorimotor striatal-thalamo-cortical networks in DAT-tg
rats.
Finally, GTS is a complex disorder with highly variable
phenotypic manifestations and high frequency of comorbidities
(Qi et al., 2017). It is possible that the effects of tDCS
treatment depend on a variety of genomic variants and
chromosomal aberrations making a linear tDCS effect in the
whole patient sample unlikely and showing the need for a further
characterization of genetic subtypes and their impact on tDCS
efficacy.
Thus, development of tDCS under use of translational
research options rather than single-case guided research
may represent an alternative and promising strategy towards
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development of tDCS as potential treatment for GTS. Finally,
there may be a need to define tDCS intensities based on electrical
field modeling than applying fixed tDCS intensities (Lisanby,
2017).
CONCLUSION
Our case series shows that modulating cortical excitability in GTS
has not yet been developed to a clinically applicable treatment.
A proof-of-concept study in humans is still lacking. Due to the
variety and complexity of cortical regions involved in GTS, there
is a multitude of possible tDCS approaches but also interferences
that inhibit prognoses of, or change expected results. Our results
hint that future research will have to focus on the determination
of most effective stimulation modes regarding site, polarity and
frequentness in a first step before exploring tDCS in a larger
clinical setting.
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